English

China SXT Pharmaceuticals, Inc.

EDGAR

SXTC Report (type unavailable) · filed 2026-10-09

70 filing records in this dataset, filed from 2017-12-04 to 2026-10-09. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest fiscal year

Revenue

1.93 million USD

2024 · USD

Exact inputs and evidence

Revenue: 1928497 USD Source

Cash and cash equivalents: 28.2 million uref_1638897415 2026-03-31 Source
Exact value

28175865 uref_1638897415
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-09.

Financial data available through: 2026-03-31.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2024-03-31
Operating income: 3 of 11 periods available· newest 2026-03-31
Net income: 3 of 11 periods available· newest 2026-03-31
Operating cash flow: 3 of 11 periods available· newest 2026-03-31
Capital expenditure: 2 of 11 periods available· newest 2025-03-31
Total assets: 2 of 11 periods available· newest 2026-03-31
Total liabilities: 2 of 11 periods available· newest 2026-03-31
Current assets: 2 of 11 periods available· newest 2026-03-31
Current liabilities: 2 of 11 periods available· newest 2026-03-31
Cash and cash equivalents: 2 of 11 periods available· newest 2026-03-31
Long-term debt including current maturities: Multiple units; comparison withheld· newest 2025-03-31
Shares outstanding: Multiple units; comparison withheld· newest 2025-03-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−uref_1638897415 2.9 million

Prior period

−uref_1638897415 3.3 million

2024-04-01 – 2025-03-31
Current period

−uref_1638897415 6.21 million

2025-04-01 – 2026-03-31

Exact inputs and evidence

-6205085 − -3303652 = -2901433 uref_1638897415

-3303652 uref_1638897415 · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
-6205085 uref_1638897415 · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · China SXT Pharmaceuticals, Inc. · 2026-03-31 China SXT Pharmaceuticals, Inc. (edgar:1723980) Year-over-year change in Net income: -2901433 uref_1638897415 Concept: fundies:NetIncome Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T18:37:32Z Snapshot: 42d57cf32dc47b23e4520c5ef044525b71ed0c6a52ba9eee8289ac5a5ca753d9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1723980?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -6205085 uref_1638897415 (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1602116 Filing: 000121390026074310 Input fundies:NetIncome: -3303652 uref_1638897415 (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1602489 Filing: 000121390026074310
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−uref_1638897415 1.67 million

Prior period

−uref_1638897415 2.35 million

2024-04-01 – 2025-03-31
Current period

−uref_1638897415 4.02 million

2025-04-01 – 2026-03-31

Exact inputs and evidence

-4017456 − -2345333 = -1672123 uref_1638897415

-2345333 uref_1638897415 · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
-4017456 uref_1638897415 · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · China SXT Pharmaceuticals, Inc. · 2026-03-31 China SXT Pharmaceuticals, Inc. (edgar:1723980) Year-over-year change in Operating cash flow: -1672123 uref_1638897415 Concept: fundies:OperatingCashFlow Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T18:37:32Z Snapshot: 42d57cf32dc47b23e4520c5ef044525b71ed0c6a52ba9eee8289ac5a5ca753d9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1723980?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -4017456 uref_1638897415 (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1630654 Filing: 000121390026074310 Input fundies:OperatingCashFlow: -2345333 uref_1638897415 (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1631207 Filing: 000121390026074310
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2023-04-01 – 2024-03-31

Revenue USD 1.93 million 100% of revenue
Operating costs Derived Unavailable An input is unavailable.
Operating income Unavailable An input is unavailable.
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow Unavailable An input is unavailable.
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2016-04-01 – 2017-03-31	4881523	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2016-04-01 – 2017-03-31: 4881523 USD Inspect Revenue Open source
2018 2017-04-01 – 2018-03-31	7019243	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2017-04-01 – 2018-03-31: 7019243 USD Inspect Revenue Open source
2019 2018-04-01 – 2019-03-31	7012026	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2018-04-01 – 2019-03-31: 7012026 USD Inspect Revenue Open source
2020 2019-04-01 – 2020-03-31	5162268	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2019-04-01 – 2020-03-31: 5162268 USD Inspect Revenue Open source
2021 2020-04-01 – 2021-03-31	4777573	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2020-04-01 – 2021-03-31: 4777573 USD Inspect Revenue Open source
2022 2021-04-01 – 2022-03-31	2602281	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2021-04-01 – 2022-03-31: 2602281 USD Inspect Revenue Open source
2023 2022-04-01 – 2023-03-31	1971679	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2022-04-01 – 2023-03-31: 1971679 USD Inspect Revenue Open source
2024 2023-04-01 – 2024-03-31	1928497	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2023-04-01 – 2024-03-31: 1928497 USD Inspect Revenue Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 1.9M 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-03-31	Revenue	4881523	Revenue: 4881523 Open source
20182018-03-31	Revenue	7019243	Revenue: 7019243 Open source
20192019-03-31	Revenue	7012026	Revenue: 7012026 Open source
20202020-03-31	Revenue	5162268	Revenue: 5162268 Open source
20212021-03-31	Revenue	4777573	Revenue: 4777573 Open source
20222022-03-31	Revenue	2602281	Revenue: 2602281 Open source
20232023-03-31	Revenue	1971679	Revenue: 1971679 Open source
20242024-03-31	Revenue	1928497	Revenue: 1928497 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-2.2% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-03-31	Year over year	No prior comparable period	Revenue: 4881523 Open source
20182018-03-31	Year over year	43.8%	Revenue: 7019243 Open source Revenue: 4881523 Open source
20192019-03-31	Year over year	-0.1%	Revenue: 7012026 Open source Revenue: 7019243 Open source
20202020-03-31	Year over year	-26.4%	Revenue: 5162268 Open source Revenue: 7012026 Open source
20212021-03-31	Year over year	-7.5%	Revenue: 4777573 Open source Revenue: 5162268 Open source
20222022-03-31	Year over year	-45.5%	Revenue: 2602281 Open source Revenue: 4777573 Open source
20232023-03-31	Year over year	-24.2%	Revenue: 1971679 Open source Revenue: 2602281 Open source
20242024-03-31	Year over year	-2.2%	Revenue: 1928497 Open source Revenue: 1971679 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2017-03-31	Operating margin	Not reported	Revenue: 4881523 Open source
2018-03-31	Operating margin	Not reported	Revenue: 7019243 Open source
2019-03-31	Operating margin	Not reported	Revenue: 7012026 Open source
2020-03-31	Operating margin	Not reported	Revenue: 5162268 Open source
2021-03-31	Operating margin	Not reported	Revenue: 4777573 Open source
2022-03-31	Operating margin	Not reported	Revenue: 2602281 Open source
2023-03-31	Operating margin	Not reported	Revenue: 1971679 Open source
2024-03-31	Operating margin	Not reported	Revenue: 1928497 Open source
2017-03-31	Net margin	Not reported	Revenue: 4881523 Open source
2018-03-31	Net margin	Not reported	Revenue: 7019243 Open source
2019-03-31	Net margin	Not reported	Revenue: 7012026 Open source
2020-03-31	Net margin	Not reported	Revenue: 5162268 Open source
2021-03-31	Net margin	Not reported	Revenue: 4777573 Open source
2022-03-31	Net margin	Not reported	Revenue: 2602281 Open source
2023-03-31	Net margin	Not reported	Revenue: 1971679 Open source
2024-03-31	Net margin	Not reported	Revenue: 1928497 Open source
20172017-03-31	Free cash flow margin	Not reported	Revenue: 4881523 Open source
20182018-03-31	Free cash flow margin	Not reported	Revenue: 7019243 Open source
20192019-03-31	Free cash flow margin	Not reported	Revenue: 7012026 Open source
20202020-03-31	Free cash flow margin	Not reported	Revenue: 5162268 Open source
20212021-03-31	Free cash flow margin	Not reported	Revenue: 4777573 Open source
20222022-03-31	Free cash flow margin	Not reported	Revenue: 2602281 Open source
20232023-03-31	Free cash flow margin	Not reported	Revenue: 1971679 Open source
20242024-03-31	Free cash flow margin	Not reported	Revenue: 1928497 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-03-31	Operating cash flow	Not reported	No source recorded
20182018-03-31	Operating cash flow	Not reported	No source recorded
20192019-03-31	Operating cash flow	Not reported	No source recorded
20202020-03-31	Operating cash flow	Not reported	No source recorded
20212021-03-31	Operating cash flow	Not reported	No source recorded
20222022-03-31	Operating cash flow	Not reported	No source recorded
20232023-03-31	Operating cash flow	Not reported	No source recorded
20242024-03-31	Operating cash flow	Not reported	No source recorded

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value	Source evidence
20172017-03-31	Free cash flow	Unavailable	No source recorded
20182018-03-31	Free cash flow	Unavailable	No source recorded
20192019-03-31	Free cash flow	Unavailable	No source recorded
20202020-03-31	Free cash flow	Unavailable	No source recorded
20212021-03-31	Free cash flow	Unavailable	No source recorded
20222022-03-31	Free cash flow	Unavailable	No source recorded
20232023-03-31	Free cash flow	Unavailable	No source recorded
20242024-03-31	Free cash flow	Unavailable	No source recorded

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2017-03-31	Liabilities / assets	Not reported	No source recorded
2018-03-31	Liabilities / assets	Not reported	No source recorded
2019-03-31	Liabilities / assets	Not reported	No source recorded
2020-03-31	Liabilities / assets	Not reported	No source recorded
2021-03-31	Liabilities / assets	Not reported	No source recorded
2022-03-31	Liabilities / assets	Not reported	No source recorded
2023-03-31	Liabilities / assets	Not reported	No source recorded
2024-03-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2017-03-31	Current assets / current liabilities	Not reported	No source recorded
2018-03-31	Current assets / current liabilities	Not reported	No source recorded
2019-03-31	Current assets / current liabilities	Not reported	No source recorded
2020-03-31	Current assets / current liabilities	Not reported	No source recorded
2021-03-31	Current assets / current liabilities	Not reported	No source recorded
2022-03-31	Current assets / current liabilities	Not reported	No source recorded
2023-03-31	Current assets / current liabilities	Not reported	No source recorded
2024-03-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2024 2023-04-01 – 2024-03-31	−uref_1638897415 3.1 million Exact value Exact value: -3098532 uref_1638897415 2023-04-01 – 2024-03-31: -3098532 uref_1638897415 Inspect Net Income Open source Share or cite Citation for Net Income · China SXT Pharmaceuticals, Inc. · 2024-03-31 China SXT Pharmaceuticals, Inc. (edgar:1723980) Net Income: -3098532 uref_1638897415 Concept: fundies:NetIncome Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T18:37:32Z Snapshot: 42d57cf32dc47b23e4520c5ef044525b71ed0c6a52ba9eee8289ac5a5ca753d9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1723980/explain?concept=fundies%3ANetIncome&period=2024-03-31&surface=latest&period_type=duration&start=2023-04-01&unit=uref_1638897415&dimensions= Input fundies:NetIncome: -3098532 uref_1638897415 (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1602863 Filing: 000121390026074310 The citation records this snapshot. The page link may show a newer release later.	−uref_1638897415 1.93 million Exact value Exact value: -1928053 uref_1638897415 2023-04-01 – 2024-03-31: -1928053 uref_1638897415 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · China SXT Pharmaceuticals, Inc. · 2024-03-31 China SXT Pharmaceuticals, Inc. (edgar:1723980) Operating Cash Flow: -1928053 uref_1638897415 Concept: fundies:OperatingCashFlow Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T18:37:32Z Snapshot: 42d57cf32dc47b23e4520c5ef044525b71ed0c6a52ba9eee8289ac5a5ca753d9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1723980/explain?concept=fundies%3AOperatingCashFlow&period=2024-03-31&surface=latest&period_type=duration&start=2023-04-01&unit=uref_1638897415&dimensions= Input fundies:OperatingCashFlow: -1928053 uref_1638897415 (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1631761 Filing: 000121390026074310 The citation records this snapshot. The page link may show a newer release later.	uref_1638897415 7,063 Exact value Exact value: 7063 uref_1638897415 2023-04-01 – 2024-03-31: 7063 uref_1638897415 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · China SXT Pharmaceuticals, Inc. · 2024-03-31 China SXT Pharmaceuticals, Inc. (edgar:1723980) Capital Expenditure: 7063 uref_1638897415 Concept: fundies:CapitalExpenditure Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T18:37:32Z Snapshot: 42d57cf32dc47b23e4520c5ef044525b71ed0c6a52ba9eee8289ac5a5ca753d9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1723980/explain?concept=fundies%3ACapitalExpenditure&period=2024-03-31&surface=latest&period_type=duration&start=2023-04-01&unit=uref_1638897415&dimensions= Input fundies:CapitalExpenditure: 7063 uref_1638897415 (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1634442 Filing: 000121390026074310 The citation records this snapshot. The page link may show a newer release later.	−uref_1638897415 1.94 million Calculation and evidence -1928053 − 7063 uref_1638897415 Exact free cash flow: -1935116 uref_1638897415 2023-04-01 – 2024-03-31: -1928053 uref_1638897415 · Inspect Operating Cash Flow · Source 2023-04-01 – 2024-03-31: 7063 uref_1638897415 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · China SXT Pharmaceuticals, Inc. · 2024-03-31 China SXT Pharmaceuticals, Inc. (edgar:1723980) Free cash flow: -1935116 uref_1638897415 Concept: free-cash-flow Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T18:37:32Z Snapshot: 42d57cf32dc47b23e4520c5ef044525b71ed0c6a52ba9eee8289ac5a5ca753d9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1723980?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1928053 uref_1638897415 (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1631761 Filing: 000121390026074310 Input fundies:CapitalExpenditure: 7063 uref_1638897415 (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1634442 Filing: 000121390026074310 The citation records this snapshot. The page link may show a newer release later.
2025 2024-04-01 – 2025-03-31	−uref_1638897415 3.3 million Exact value Exact value: -3303652 uref_1638897415 2024-04-01 – 2025-03-31: -3303652 uref_1638897415 Inspect Net Income Open source Share or cite Citation for Net Income · China SXT Pharmaceuticals, Inc. · 2025-03-31 China SXT Pharmaceuticals, Inc. (edgar:1723980) Net Income: -3303652 uref_1638897415 Concept: fundies:NetIncome Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T18:37:32Z Snapshot: 42d57cf32dc47b23e4520c5ef044525b71ed0c6a52ba9eee8289ac5a5ca753d9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1723980/explain?concept=fundies%3ANetIncome&period=2025-03-31&surface=latest&period_type=duration&start=2024-04-01&unit=uref_1638897415&dimensions= Input fundies:NetIncome: -3303652 uref_1638897415 (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1602489 Filing: 000121390026074310 The citation records this snapshot. The page link may show a newer release later.	−uref_1638897415 2.35 million Exact value Exact value: -2345333 uref_1638897415 2024-04-01 – 2025-03-31: -2345333 uref_1638897415 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · China SXT Pharmaceuticals, Inc. · 2025-03-31 China SXT Pharmaceuticals, Inc. (edgar:1723980) Operating Cash Flow: -2345333 uref_1638897415 Concept: fundies:OperatingCashFlow Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T18:37:32Z Snapshot: 42d57cf32dc47b23e4520c5ef044525b71ed0c6a52ba9eee8289ac5a5ca753d9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1723980/explain?concept=fundies%3AOperatingCashFlow&period=2025-03-31&surface=latest&period_type=duration&start=2024-04-01&unit=uref_1638897415&dimensions= Input fundies:OperatingCashFlow: -2345333 uref_1638897415 (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1631207 Filing: 000121390026074310 The citation records this snapshot. The page link may show a newer release later.	uref_1638897415 2,023 Exact value Exact value: 2023 uref_1638897415 2024-04-01 – 2025-03-31: 2023 uref_1638897415 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · China SXT Pharmaceuticals, Inc. · 2025-03-31 China SXT Pharmaceuticals, Inc. (edgar:1723980) Capital Expenditure: 2023 uref_1638897415 Concept: fundies:CapitalExpenditure Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T18:37:32Z Snapshot: 42d57cf32dc47b23e4520c5ef044525b71ed0c6a52ba9eee8289ac5a5ca753d9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1723980/explain?concept=fundies%3ACapitalExpenditure&period=2025-03-31&surface=latest&period_type=duration&start=2024-04-01&unit=uref_1638897415&dimensions= Input fundies:CapitalExpenditure: 2023 uref_1638897415 (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1634098 Filing: 000121390026074310 The citation records this snapshot. The page link may show a newer release later.	−uref_1638897415 2.35 million Calculation and evidence -2345333 − 2023 uref_1638897415 Exact free cash flow: -2347356 uref_1638897415 2024-04-01 – 2025-03-31: -2345333 uref_1638897415 · Inspect Operating Cash Flow · Source 2024-04-01 – 2025-03-31: 2023 uref_1638897415 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · China SXT Pharmaceuticals, Inc. · 2025-03-31 China SXT Pharmaceuticals, Inc. (edgar:1723980) Free cash flow: -2347356 uref_1638897415 Concept: free-cash-flow Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T18:37:32Z Snapshot: 42d57cf32dc47b23e4520c5ef044525b71ed0c6a52ba9eee8289ac5a5ca753d9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1723980?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2345333 uref_1638897415 (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1631207 Filing: 000121390026074310 Input fundies:CapitalExpenditure: 2023 uref_1638897415 (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1634098 Filing: 000121390026074310 The citation records this snapshot. The page link may show a newer release later.
2026 2025-04-01 – 2026-03-31	−uref_1638897415 6.21 million Exact value Exact value: -6205085 uref_1638897415 2025-04-01 – 2026-03-31: -6205085 uref_1638897415 Inspect Net Income Open source Share or cite Citation for Net Income · China SXT Pharmaceuticals, Inc. · 2026-03-31 China SXT Pharmaceuticals, Inc. (edgar:1723980) Net Income: -6205085 uref_1638897415 Concept: fundies:NetIncome Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T18:37:32Z Snapshot: 42d57cf32dc47b23e4520c5ef044525b71ed0c6a52ba9eee8289ac5a5ca753d9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1723980/explain?concept=fundies%3ANetIncome&period=2026-03-31&surface=latest&period_type=duration&start=2025-04-01&unit=uref_1638897415&dimensions= Input fundies:NetIncome: -6205085 uref_1638897415 (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1602116 Filing: 000121390026074310 The citation records this snapshot. The page link may show a newer release later.	−uref_1638897415 4.02 million Exact value Exact value: -4017456 uref_1638897415 2025-04-01 – 2026-03-31: -4017456 uref_1638897415 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · China SXT Pharmaceuticals, Inc. · 2026-03-31 China SXT Pharmaceuticals, Inc. (edgar:1723980) Operating Cash Flow: -4017456 uref_1638897415 Concept: fundies:OperatingCashFlow Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T18:37:32Z Snapshot: 42d57cf32dc47b23e4520c5ef044525b71ed0c6a52ba9eee8289ac5a5ca753d9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1723980/explain?concept=fundies%3AOperatingCashFlow&period=2026-03-31&surface=latest&period_type=duration&start=2025-04-01&unit=uref_1638897415&dimensions= Input fundies:OperatingCashFlow: -4017456 uref_1638897415 (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm#1630654 Filing: 000121390026074310 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

70 filings · 1,104 latest values · 1,104 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001723980, 1723980, SXTC, edgar:1723980

Also known as CHINA SXT PHARMACEUTICALS, INC., China SXT Pharmaceuticals, Inc.

China SXT Pharmaceuticals, Inc.

Latest fiscal year

Revenue

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

2024 2023-04-01 – 2024-03-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation